John Byon
Director Técnico/Científico/I+D en IMUGENE LIMITED .
Origen de la red de primer grado John Byon.
| Entidad | Tipo de entidad | Industria | |
|---|---|---|---|
| Public Company | Biotechnology | 16 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a John Byon a través de su red personal
| Empresa | Sector | Personas relacionadas | Puesto principal |
|---|---|---|---|
| CHIMERIC THERAPEUTICS LIMITED | Biotechnology | Director/Board Member Founder Director/Board Member | |
| EXELIXIS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
| SCOPUS BIOPHARMA INC. | Pharmaceuticals: Other | Director/Board Member Chairman | |
| The University of New South Wales | College/University | Undergraduate Degree Doctorate Degree | |
| ENANTA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| PYXIS ONCOLOGY, INC. | Pharmaceuticals: Major | Director/Board Member | |
Apexigen America, Inc.
 Apexigen America, Inc. Pharmaceuticals: MajorHealth Technology Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA. | Pharmaceuticals: Major | Director/Board Member | |
| APEXIGEN, INC. | Biotechnology | Director/Board Member | |
Sofinnova Investments, Inc.
 Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Investment Managers | Private Equity Investor | |
| AMBRX INC | Pharmaceuticals: Major | Consultant / Advisor | |
Cephalon, Inc.
 Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| ATARA BIOTHERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Monash University
 Monash University Other Consumer ServicesConsumer Services Monash University operates as a public research university. It specializes in higher education, global engagement, postgraduate courses, undergraduate study, and PhD research. The company was founded on March 1961 and is headquartered in Clayton, Australia. | College/University | Doctorate Degree | |
| Eden Peptide Pty Ltd. | Director/Board Member | ||
Mimotopes Pty Ltd.
 Mimotopes Pty Ltd. Pharmaceuticals: OtherHealth Technology Mimotopes Pty Ltd is an industry leader in the peptide and discovery chemistry sector. Mimotopes develops, markets and distributes high quality biochemical products and services for the life-science sector. Their customers range from small labs and universities worldwide, to large multinational drug discovery companies. Their core competence covers the following areas: ' Custom Peptides Mimotopes' custom peptides are synthesized in modern, automated synthesizers using advanced solid phase techniques. The value in using Mimotopes custom peptides is not only that they offer a wide range of peptide lengths, purities and quantities. Their customers can also draw on the exceptional experience of their technical staff, who consult with them to design the peptide application that gives the best possible research outcome. ' PepSets Peptide Libraries Peptide libraries for various screening applications in Proteomics, Immunology and Drug Discovery. PepSets peptide libraries provide researchers with a rapid and cost effective solution for an immense range of bioactivity screening purposes. These sets of custom synthesized peptides enable fast, efficient results. ' Peptide Reagents High-quality amino acids and peptide synthesis reagents. The same reagents that Mimotopes uses in its in-house production system. ' SynPhase Lanterns Modular solid phase supports for organic synthesis, combinatorial chemistry, peptide chemistry, molecule scavenging and affinity applications. Convenient to handle, SynPhase Lanterns are the unique and reliable alternative to using conventional resins for solid-phase synthetic chemistry. Not only do SynPhase Lanterns provide superior reaction kinetics, but their unrivalled ease of handling results in less errors, better traceability and ultimately, faster, more accurate results. | Pharmaceuticals: Other | Director/Board Member | |
Novartis Australia Pty Ltd.
 Novartis Australia Pty Ltd. BiotechnologyHealth Technology Novartis Australia Pty Ltd. engages in the marketing and wholesale of pharmaceutical products in Australia. The company is headquartered in North Ryde, Australia. | Biotechnology | Corporate Officer/Principal | |
| Adistem Pty Ltd. | Chief Executive Officer | ||
Eterna Therapeutics LLC
 Eterna Therapeutics LLC Pharmaceuticals: MajorHealth Technology Part of Eterna Therapeutics, Inc., Eterna Therapeutics LLC is a clinical-stage biopharmaceutical company based in New York, NY. The company is focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer. Eterna Therapeutics is committed to developing irx-2, a novel cytokine-based therapy, to treat patients with cancer. The active constituents of irx-2, namely interleukin-2 (il-2) and other key cytokines, are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. Eterna Therapeutics is a late clinical-stage biopharmaceutical company focused on il-2 cytokine-based therapies in treating patients with cancer. Eterna Therapeutics was acquired by NTN Buzztime, Inc. on March 25, 2021 for $213.30 million. | Pharmaceuticals: Major | Chief Operating Officer | |
| Rutgers State University of New Jersey | College/University | Doctorate Degree | |
| RHINOMED | Medical Specialties | Chief Tech/Sci/R&D Officer | |
| New York University | College/University | Graduate Degree | |
| GOSSAMER BIO, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Bioscience Oncology Pty Ltd. | Chairman | ||
Pacific Council on International Policy
 Pacific Council on International Policy Miscellaneous Commercial ServicesCommercial Services Pacific Council on International Policy operates as a foreign affairs firm. The firm specializes International Affairs, International Relations, Foreign Policy, Foreign Affairs, Public Policy, National Security, International Economics, Government, Professional Networking, Events, Non Profit, International Policy and International Business, Analysis. The company was founded in 1995 and is headquartered in Los Angeles, CA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Biolife Science Ltd.
 Biolife Science Ltd. Pharmaceuticals: OtherHealth Technology Part of Imugene Ltd., Biolife Science Ltd. is an Australian company that manufactures cancer therapeutic vaccines. The company is based in Brisbane, Australia. The company was founded by Brian Leedman. Biolife Science was acquired by Imugene Ltd. from Acuvax Ltd. on December 20, 2013 for $4.08 million. | Pharmaceuticals: Other | Director/Board Member | |
| PRESCIENT THERAPEUTICS LIMITED | Biotechnology | Founder | |
Pathway Oncology Pty Ltd.
 Pathway Oncology Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Prescient Therapeutics Ltd., Pathway Oncology Pty Ltd. holds a license to anti-cancer technology. The Australian company was founded by Paul A. Hopper. Pathway Oncology was acquired by Prescient Therapeutics Ltd. on May 30, 2014 for $1.74 million. | Miscellaneous Commercial Services | Founder | |
| AROVELLA THERAPEUTICS LIMITED | Pharmaceuticals: Major | Chairman | |
Vaxinia Pty Ltd.
 Vaxinia Pty Ltd. Pharmaceuticals: OtherHealth Technology Vaxinia Pty Ltd. develops oncolytic cancer viruses. The company is headquartered in Australia. | Pharmaceuticals: Other | Chairman | |
| C19 Therapeutics Pty Ltd. | Director/Board Member | ||
| Weill Cornell Medical College | College/University | Doctorate Degree | |
| RADIOPHARM THERANOSTICS LIMITED | Medical/Nursing Services | Chairman | |
Glioblast Pty Ltd.
 Glioblast Pty Ltd. Pharmaceuticals: MajorHealth Technology Glioblast Pty Ltd. engages in neuro-oncology business. The company is headquartred in Sydney, Australia. | Pharmaceuticals: Major | Founder | |
Radiopharm Theranostics (USA), Inc.
 Radiopharm Theranostics (USA), Inc. Pharmaceuticals: MajorHealth Technology Radiopharm Theranostics (USA), Inc. is an American company founded in 2021 that develops radiopharmaceutical products for diagnostic and therapeutic uses. | Pharmaceuticals: Major | President | |
| ONCOMED PHARMACEUTICALS INC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Memorial Sloan Kettering Cancer Center
 Memorial Sloan Kettering Cancer Center Hospital/Nursing ManagementHealth Services Memorial Sloan-Kettering Cancer Center operates as a private cancer center. It offers cancer care services to adult; and child and teen patients. Its services include risk assessment and screening; diagnosis and treatment; clinical trials; patient and caregiver education; and pediatric clinical trials. The company was founded by John J. Astor and Charlotte Astor in 1884 and is headquartered in New York, NY. | Hospital/Nursing Management | Corporate Officer/Principal | |
| Vassar College | College/University | Undergraduate Degree | |
| LTR PHARMA LIMITED | Biotechnology | Chief Operating Officer | |
WindMIL Therapeutics, Inc.
 WindMIL Therapeutics, Inc. Medical SpecialtiesHealth Technology WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD. | Medical Specialties | Corporate Officer/Principal | |
| University of Buckingham | College/University | Undergraduate Degree | |
| University of California San Diego | College/University | Undergraduate Degree | |
Immune-Onc Therapeutics, Inc.
 Immune-Onc Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Immune-Onc Therapeutics, Inc. operates as a biopharmaceutical company focused on developing innovative therapeutic antibodies for cancer treatment. The company was founded by Charlene Liao and Gui-Liang Yu in 2016 and is headquartered in Palo Alto, CA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| CELULARITY INC. | Miscellaneous Commercial Services | Chief Operating Officer | |
| KITE PHARMA INC | Biotechnology | Corporate Officer/Principal | |
| The University of Colorado | College/University | Doctorate Degree | |
| Rady School of Management at UC San Diego | College/University | Masters Business Admin |
Estadísticas
Internacional
| Estados Unidos | 31 |
| Australia | 20 |
| Reino Unido | 2 |
Sectorial
| Health Technology | 30 |
| Consumer Services | 11 |
| Commercial Services | 4 |
| Health Services | 3 |
| Finance | 2 |
Operativa
| Director/Board Member | 63 |
| Corporate Officer/Principal | 30 |
| Chief Tech/Sci/R&D Officer | 28 |
| Independent Dir/Board Member | 18 |
| Director of Finance/CFO | 17 |
Las relaciones más conectadas
| Insiders | |
|---|---|
| Paul Hopper | 33 |
| Jens Eckstein | 27 |
| Kimberlee Drapkin | 23 |
| Lesley Russell | 19 |
| Jakob Dupont | 14 |
| Michael Tonroe | 12 |
| Nick Ede | 8 |
| Monil Shah | 7 |
| Bradley Glover | 7 |
| Ron Weitzman | 7 |
| Leslie Chong | 6 |
| Joseph Woodard | 5 |
| Ursula Wiedermann | 4 |
| Ursula McCurry | 4 |
| Anthony Good | 3 |
- Bolsa de valores
- Insiders
- John Byon
- Conexiones Empresas
